Intensity Therapeutics, Inc. financial data

Symbol
INTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
61 Wilton Road, 3 Rd Floor, Westport, CT
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 487 %
Debt-to-equity 25 %
Return On Equity -137 %
Return On Assets -109 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.8M shares +0.64%
Common Stock, Shares, Outstanding 13.7M shares +4.68%
Entity Public Float 22M USD
Common Stock, Value, Issued 1K USD -23.7%
Weighted Average Number of Shares Outstanding, Basic 13.7M shares +290%
Weighted Average Number of Shares Outstanding, Diluted 13.7M shares +290%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.53M USD +315%
General and Administrative Expense 6.13M USD +316%
Operating Income (Loss) -15.7M USD -315%
Net Income (Loss) Attributable to Parent -15.1M USD -34.3%
Earnings Per Share, Basic -0.26 USD/shares +74.8%
Earnings Per Share, Diluted -0.26 USD/shares +74.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.24M USD +2287%
Marketable Securities, Current 8.96M USD
Cash, Cash Equivalents, and Short-term Investments 6.3M USD
Other Assets, Current 6K USD -92.1%
Assets, Current 7.44M USD -58.8%
Operating Lease, Right-of-Use Asset 135K USD
Other Assets, Noncurrent 1.1M USD +555%
Assets 8.67M USD -52.4%
Accounts Payable, Current 1.92M USD +21.3%
Employee-related Liabilities, Current 419K USD -0.83%
Accrued Liabilities, Current 1.26M USD -14.8%
Liabilities, Current 3.2M USD +4.76%
Operating Lease, Liability, Noncurrent 124K USD
Other Liabilities, Noncurrent 0 USD
Liabilities 3.33M USD +7.55%
Retained Earnings (Accumulated Deficit) -60.1M USD -33.5%
Stockholders' Equity Attributable to Parent 5.35M USD -64.7%
Liabilities and Equity 8.67M USD -52.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.37M USD -385%
Net Cash Provided by (Used in) Financing Activities 8K USD -96.1%
Net Cash Provided by (Used in) Investing Activities 3.26M USD
Common Stock, Shares Authorized 135M shares 0%
Common Stock, Shares, Issued 13.7M shares +4.68%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD -57.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.24M USD +2283%
Deferred Tax Assets, Valuation Allowance 12M USD +18.7%
Deferred Tax Assets, Gross 12M USD +18.7%
Operating Lease, Liability 151K USD
Lessee, Operating Lease, Liability, to be Paid 176K USD
Operating Lease, Liability, Current 27K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 37K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 36K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 25K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 39K USD
Deferred Tax Assets, Operating Loss Carryforwards 8.61M USD +6.92%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 39K USD
Operating Lease, Payments 3K USD -93.9%
Additional Paid in Capital 65.4M USD +8.79%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39K USD +30%
Share-based Payment Arrangement, Expense 2.52M USD +89.4%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares